Jack in The Australian today - $$ to come, page-103

@rgc68 I think your comments are a bit harsh regarding the company's past. It's current board and management and advisory board are appropriate for the task at hand. From what I hear all of the "old guard" have moved on, so the comparison is a little unfair.

Securing CE Mark and in time FDA will be significant milestones, which will set it apart from the lifestyle apps you refer to. Certainly validation will remain an issue, which the company will continue to work on beyond regulatory approvals. Validation does not stop with regulatory approval. The work at Mayo Clinic over the next 5 years will see to that; and let's not forget the collaboration with Otsuka.

In terms of valuation, we are all hopeful that it will improve as milestones are hit and importantly, revenue commences, regardless of how modest to begin with.